Today on The Mary Jane Society, we're joined by Shane Johnson, a Stanford-trained medical doctor and accomplished biotech entrepreneur. Shane is the co-founder of BayMedica, a pioneering manufacturer of rare and minor cannabinoid ingredients known for their exceptional purity, consistency, and scalability traits critical to the future of pharmaceutical-grade cannabinoid products.

BayMedica was acquired by InMed Pharmaceuticals, a NASDAQ-listed, clinical-stage pharmaceutical company based in Canada. InMed is developing a robust pipeline of proprietary small molecule drug candidates that target the CB1 and CB2 receptors of the endocannabinoid system. Their current research programs focus on therapeutic treatments for Alzheimer's disease, as well as ocular and dermatological conditions.

Dive into Shane's insights on cannabinoid drug development, the regulatory landscape, and the future of pharmaceutical innovation in cannabis.

https://www.linkedin.com/in/shanejohnson3

https://www.baymedica.com

https://www.inmedpharma.com

The Mary Jane Society is produced and hosted by Pam Chmiel, a journalist, freelance writer, and marketing and PR specialist in the cannabis industry. Get in touch to discuss your business strategy or explore working together at pam@TheMaryJaneSociety.com.

LinkedIn Twitter Instagram

Please like the show to help us reach more listeners🙏🏻